(JNJ) Johnson & Johnson - Ratings and Ratios
Pharmaceuticals, MedicalDevices, ContactLenses, SurgicalTools, Orthopaedics
JNJ EPS (Earnings per Share)
JNJ Revenue
Description: JNJ Johnson & Johnson
Johnson & Johnson is a global healthcare company operating through two main segments: Innovative Medicine and MedTech. The Innovative Medicine segment focuses on developing treatments for various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolism. Notable areas of focus include rheumatoid arthritis, HIV/AIDS, mood disorders, and prostate cancer. The companys diverse portfolio is designed to address a wide range of medical needs, positioning it as a leader in the pharmaceutical industry.
The MedTech segment offers a broad range of medical technologies, including electrophysiology products, heart recovery portfolios, and orthopaedics products. Johnson & Johnsons MedTech division is also known for its contact lenses under the ACUVUE brand and TECNIS intraocular lenses for cataract surgery. With a presence in multiple medical specialties, the company is well-positioned to capitalize on advancements in medical technology.
From a financial perspective, Johnson & Johnson has demonstrated strong performance, with a Return on Equity (RoE) of 29.95%. The companys market capitalization stands at approximately $379.4 billion, indicating its significant size and influence in the market. Additionally, Johnson & Johnson has a history of paying consistent dividends, making it an attractive option for income-focused investors. The companys P/E ratio of 17.54 and forward P/E of 14.77 suggest a relatively stable valuation compared to its earnings growth prospects.
Key Performance Indicators (KPIs) such as revenue growth, R&D expenditure as a percentage of sales, and the number of new product launches can provide further insights into Johnson & Johnsons operational efficiency and innovation pipeline. For instance, a high R&D spend can indicate the companys commitment to developing new treatments and technologies, potentially driving future growth. Monitoring these KPIs can help investors assess the companys long-term prospects and its ability to maintain its competitive edge in the healthcare industry.
JNJ Stock Overview
| Market Cap in USD | 430,924m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 1944-09-24 |
JNJ Stock Ratings
| Growth Rating | 30.7% |
| Fundamental | 75.3% |
| Dividend Rating | 59.9% |
| Return 12m vs S&P 500 | -6.11% |
| Analyst Rating | 3.75 of 5 |
JNJ Dividends
| Dividend Yield 12m | 3.07% |
| Yield on Cost 5y | 3.82% |
| Annual Growth 5y | 4.29% |
| Payout Consistency | 85.2% |
| Payout Ratio | 43.2% |
JNJ Growth Ratios
| Growth Correlation 3m | 90.5% |
| Growth Correlation 12m | 24.8% |
| Growth Correlation 5y | 35.7% |
| CAGR 5y | 5.72% |
| CAGR/Max DD 5y | 0.31 |
| Sharpe Ratio 12m | 1.01 |
| Alpha | 4.56 |
| Beta | 0.187 |
| Volatility | 16.18% |
| Current Volume | 6424.7k |
| Average Volume 20d | 8927.8k |
| Stop Loss | 170.1 (-3%) |
| Signal | -1.11 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (22.66b TTM) > 0 and > 6% of Revenue (6% = 5.44b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -2.73pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 0.35% (prev 4.49%; Δ -4.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 23.03b > Net Income 22.66b (YES >=105%, WARN >=100%) |
| Net Debt (32.18b) to EBITDA (26.90b) ratio: 1.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (2.42b) change vs 12m ago -0.12% (target <= -2.0% for YES) |
| Gross Margin 67.92% (prev 69.06%; Δ -1.15pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.40% (prev 47.81%; Δ 0.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 36.75 (EBITDA TTM 26.90b / Interest Expense TTM 582.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.97
| (A) 0.00 = (Total Current Assets 54.50b - Total Current Liabilities 54.18b) / Total Assets 193.39b |
| (B) 0.86 = Retained Earnings (Balance) 165.37b / Total Assets 193.39b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) 0.11 = EBIT TTM 21.39b / Avg Total Assets 187.24b |
| (D) 1.34 = Book Value of Equity 154.19b / Total Liabilities 114.92b |
| Total Rating: 4.97 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.30
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.44% = 1.72 |
| 3. FCF Margin 18.09% = 4.52 |
| 4. Debt/Equity 0.65 = 2.30 |
| 5. Debt/Ebitda 1.89 = 0.22 |
| 6. ROIC - WACC 9.23% = 11.53 |
| 7. RoE 30.39% = 2.50 |
| 8. Rev. Trend 4.18% = 0.21 |
| 9. Rev. CAGR -0.07% = -0.01 |
| 10. EPS Trend 24.38% = 0.61 |
| 11. EPS CAGR 12.02% = 1.20 |
What is the price of JNJ shares?
Over the past week, the price has changed by -1.23%, over one month by +6.33%, over three months by +15.95% and over the past year by +10.49%.
Is Johnson & Johnson a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JNJ is around 170.55 USD . This means that JNJ is currently overvalued and has a potential downside of -2.79%.
Is JNJ a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 13
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the JNJ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 175.6 | 0.1% |
| Analysts Target Price | 169.2 | -3.6% |
| ValueRay Target Price | 185.9 | 6% |
Last update: 2025-08-23 05:03
JNJ Fundamental Data Overview
CCE Cash And Equivalents = 4.64b USD (last quarter)
P/E Trailing = 19.1574
P/E Forward = 16.6389
P/S = 4.7549
P/B = 5.4886
P/EG = 1.0878
Beta = 0.399
Revenue TTM = 90.63b USD
EBIT TTM = 21.39b USD
EBITDA TTM = 26.90b USD
Long Term Debt = 39.23b USD (from longTermDebt, last quarter)
Short Term Debt = 11.53b USD (from shortTermDebt, last quarter)
Debt = 50.76b USD (Calculated: Short Term 11.53b + Long Term 39.23b)
Net Debt = 32.18b USD (from netDebt column, last quarter)
Enterprise Value = 477.05b USD (430.92b + Debt 50.76b - CCE 4.64b)
Interest Coverage Ratio = 36.75 (Ebit TTM 21.39b / Interest Expense TTM 582.0m)
FCF Yield = 3.44% (FCF TTM 16.40b / Enterprise Value 477.05b)
FCF Margin = 18.09% (FCF TTM 16.40b / Revenue TTM 90.63b)
Net Margin = 25.00% (Net Income TTM 22.66b / Revenue TTM 90.63b)
Gross Margin = 67.92% ((Revenue TTM 90.63b - Cost of Revenue TTM 29.08b) / Revenue TTM)
Tobins Q-Ratio = 3.09 (Enterprise Value 477.05b / Book Value Of Equity 154.19b)
Interest Expense / Debt = 0.09% (Interest Expense 48.0m / Debt 50.76b)
Taxrate = 15.71% (from yearly Income Tax Expense: 2.62b / 16.69b)
NOPAT = 18.03b (EBIT 21.39b * (1 - 15.71%))
Current Ratio = 1.01 (Total Current Assets 54.50b / Total Current Liabilities 54.18b)
Debt / Equity = 0.65 (Debt 50.76b / last Quarter total Stockholder Equity 78.47b)
Debt / EBITDA = 1.89 (Net Debt 32.18b / EBITDA 26.90b)
Debt / FCF = 3.10 (Debt 50.76b / FCF TTM 16.40b)
Total Stockholder Equity = 74.56b (last 4 quarters mean)
RoA = 11.72% (Net Income 22.66b, Total Assets 193.39b )
RoE = 30.39% (Net Income TTM 22.66b / Total Stockholder Equity 74.56b)
RoCE = 18.80% (Ebit 21.39b / (Equity 74.56b + L.T.Debt 39.23b))
RoIC = 15.23% (NOPAT 18.03b / Invested Capital 118.41b)
WACC = 6.00% (E(430.92b)/V(481.69b) * Re(6.70%)) + (D(50.76b)/V(481.69b) * Rd(0.09%) * (1-Tc(0.16)))
Shares Correlation 5-Years: -100.0 | Cagr: -2.44%
Discount Rate = 6.70% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 77.56% ; FCFE base≈17.96b ; Y1≈17.12b ; Y5≈16.49b
Fair Price DCF = 122.3 (DCF Value 294.52b / Shares Outstanding 2.41b; 5y FCF grow -6.16% → 3.0% )
Revenue Correlation: 4.18 | Revenue CAGR: -0.07%
Rev Growth-of-Growth: 8.92
EPS Correlation: 24.38 | EPS CAGR: 12.02%
EPS Growth-of-Growth: -60.37
Additional Sources for JNJ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle